Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMICUS THERAPEUTICS, INC. Director's Dealing 2021

Jun 9, 2021

31523_dirs_2021-06-09_db899bb0-d7e6-4c9c-bbf8-e0af688fa7c6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-06-07

Reporting Person: Campbell Bradley L (Director, Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-07 Common Stock M 24375 $2.45 Acquired 436397 Direct
2021-06-07 Common Stock M 15223 $2.94 Acquired 451620 Direct
2021-06-07 Common Stock M 10653 $2.52 Acquired 462273 Direct
2021-06-07 Common Stock M 12345 $3.53 Acquired 474618 Direct
2021-06-07 Common Stock F 17350 $10.08 Disposed 457268 Direct
2021-06-07 Common Stock M 6623 $6.45 Acquired 463891 Direct
2021-06-07 Common Stock M 3891 $4.38 Acquired 467782 Direct
2021-06-07 Common Stock S 10514 $10.0064 Disposed 457268 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-07 Stock Options (right to buy) $2.45 M 24375 Disposed 2024-01-03 Common Stock (24375) Direct
2021-06-07 Stock Options (right to buy) $2.94 M 15223 Disposed 2024-06-26 Common Stock (15223) Direct
2021-06-07 Stock Options (right to buy) $2.52 M 10653 Disposed 2023-06-18 Common Stock (10653) Direct
2021-06-07 Stock Options (right to buy) $3.53 M 12345 Disposed 2023-01-28 Common Stock (12345) Direct
2021-06-07 Stock Options (right to buy) $6.45 M 6623 Disposed 2022-02-15 Common Stock (6623) Direct
2021-06-07 Stock Options (right to buy) $4.38 M 3891 Disposed 2022-06-04 Common Stock (3891) Direct

Footnotes

F1: Represents shares swapped to cover the strike price of 62,596 options exercised.

F2: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.065. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: All of the options were fully vested and exercisable as of the transaction date.